Evaluation of the therapeutic potential of masitinib and expression of its specific targets c‐Kit, PDGFR‐α, PDGFR‐β, and Lyn in canine prostate cancer cell lines

• Published in: Veterinary & comparative oncology Vol. 20; no. 3; pp. 641 - 652
• Main Authors: Klose, Katharina, Packeiser, Eva‐Maria, Granados‐Soler, José‐Luis, Hewicker‐Trautwein, Marion, Murua Escobar, Hugo, Nolte, Ingo
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-09-2022
• Subjects: canine; masitinib; prostate cancer; TKI; tyrosine kinase; prostate cancer; canine; masitinib; TKI; tyrosine kinase
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/vco.12817

Canine prostate cancer is classified into adenocarcinoma, transitional cell carcinoma with prostatic involvement, and mixed forms. Early metastatic spread leads to poor prognosis and limited treatment options. Masitinib is approved for the treatment of canine mast cell tumours and inhibits tyrosine kinase c‐Kit, tyrosine‐protein kinase Lyn (Lyn), and platelet‐derived growth factor receptors alpha and beta (PDGFR‐α, PDGFR‐β), which are known to be expressed in canine prostate cancer. The aim of this study was to evaluate masitinib in an in vitro model consisting of cell lines from primary prostate adenocarcinoma, the associated lymph node metastasis of the same patient, and transitional cell carcinoma. To assess the suitability of the model system, the targets of masitinib were investigated by immunocytochemistry in the cell lines and by immunohistochemistry in the respective formalin‐fixed, paraffin‐embedded (FFPE) original neoplastic tissue. After exposure to masitinib, cell viability, cell count, apoptosis induction, and protein expression of c‐Kit, Lyn, PDGFR‐α, and PDGFR‐β were assessed. To hedge the efficacy, two application protocols of masitinib (single application or 12‐h double‐dose regimen) were compared. Immunocytochemical and immunohistochemical analysis revealed increased Lyn, PDGFR‐α, and PDGFR‐β expression in cell lines and FFPE original neoplastic tissue compared to healthy prostate tissue. Masitinib exposure increased apoptosis, while the cell counts and cell viability decreased in a dose‐ and application interval‐dependent manner, with increased impact in the 12‐h double‐dose regimen. These in vitro effects of masitinib in canine prostate cancer and associated metastasis support further in vivo research and modifications of the clinical treatment protocol in future studies.